CN103550522B - A kind of Chinese medicine composition with whitening effect - Google Patents
A kind of Chinese medicine composition with whitening effect Download PDFInfo
- Publication number
- CN103550522B CN103550522B CN201310556120.5A CN201310556120A CN103550522B CN 103550522 B CN103550522 B CN 103550522B CN 201310556120 A CN201310556120 A CN 201310556120A CN 103550522 B CN103550522 B CN 103550522B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- crude drug
- radix
- topical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
A kind of Chinese medicine composition with whitening effect, be made up of with the pharmaceutic adjuvant being applicable to external Chinese medicine and Chinese medicine extract, it is characterized in that the formula of described Chinese medicine and Chinese medicine extract contains following composition with crude drug gauge: Radix Ginseng 15-40 part, Ganoderma 15-40 part, Flos Rosae Rugosae 15-40 part, Herba Spirodelae 15-40 part, Fructus Mume 5-20 part, Fructus Gleditsiae Abnormalis 15-40 part, Faeces Passeris 15-40 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 15-40 part, Radix Angelicae Dahuricae 15-40 part, Rhizoma Typhonii 15-40 part, Radix Ampelopsis 5-20 part, Flos Carthami 15-40 part, Borneolum Syntheticum 5-20 part, Lithargyrum 5-20 part.
Description
Technical field:
The invention belongs to and relate to a kind of Chinese medicine composition, particularly a kind of external preparation.
Background technology:
Chinese medicine for the preparation of whitening, brighten, the cosmetics of speckle dispelling, in prior art, existing wide coverage, discloses a kind of pharmaceutical composition being used for the treatment of chloasma gravidarum prepared with compositions such as Rhizoma Typhonii, the Rhizoma Atractylodis Macrocephalae, the Radix Angelicae Dahuricae, Radix Ampelopsis, the Pseudobulbus Bletillae (Rhizoma Bletillae), Flos Carthamis in Chinese patent literature CN10167044A.Chinese patent literature CN101978943A discloses a kind of pharmaceutical composition being active component with dog oil, Adeps Caprae seu ovis, the Radix Angelicae Dahuricae, Radix Glycyrrhizae, the Rhizoma Pinelliae, Fructus Mume, Herba Spirodelae, Fructus Gleditsiae Abnormalis, for freckle removing and whitening.Chinese patent literature CN1249174A also discloses a kind of Chinese medicine composition, with the Radix Angelicae Dahuricae, Herba Asari, Radix Angelicae Sinensis, Flos Carthami, the Rhizoma Atractylodis Macrocephalae, Herba Hedyotidis Diffusae, Fructus Cnidii, Flos Chrysanthemi Indici, Fructus Gleditsia, lead a cow in vain, Rhizoma Typhonii, the Pseudobulbus Bletillae (Rhizoma Bletillae), Semen Benincasae, Radix Ampelopsis, the Radix Astragali, Poria, Bombyx Batryticatus, Borneolum Syntheticum, Borax, Margarita powder is for active component.Chinese patent literature CN101199702A discloses a kind of Chinese medicine preparation for improving looks being active component with Margarita powder, Gypsum Fibrosum, SANGUSHI, Borneolum Syntheticum, the Rhizoma Pinelliae, Radix Ginseng, Stigma Croci, Chinese patent literature CN1500472A discloses a kind of beautifying liquid being active component with Radix Curcumae, Margarita powder, Flos Rosae Rugosae, Flos Chrysanthemi, Poria, Periostracum Cicadae, Herba Menthae, Cortex Moutan, Radix Paeoniae, Rhizoma Coptidis, Cortex Phellodendri, Radix Scutellariae, Flos Lonicerae, Flos Carthami, the Rhizoma Atractylodis Macrocephalae, Radix Ginseng, the Radix Astragali, Radix Angelicae Sinensis, Borneolum Syntheticum, Ganoderma, has treatment acne and the effect that brightens of skin care.
Test discovery, formula disclosed in above-mentioned four sections of documents through us, although the effect certain speckle dispelling can played, treat acne, improve skin quality, whitening effect not obvious and onset is comparatively slow, cannot meet user for brightening, the effect of whitening.
Chinese patent literature CN101411681A discloses a kind of compositions being active component with Radix Ginseng, Rhizoma Polygonati, Radix Asparagi, Rhizoma Typhonii, the Radix Angelicae Dahuricae, Radix Angelicae Sinensis, Bombyx Batryticatus, Fructus Xanthii, the Pseudobulbus Bletillae (Rhizoma Bletillae), Semen Benincasae, Folium Ginkgo, Rhizoma Polygonati Odorati, Fructus Tribuli, Euphorbia lathyris, Margarita powder, Lithargyrum, Herba Menthae, Placenta Hominis, Cortex Cinnamomi, Herba Duchesneae Indicae, Radix Ampelopsis, Borneolum Syntheticum, Semen phaseoli radiati powder, Radix Glycyrrhizae Preparata.Chinese patent literature CN1096195A also discloses a kind of traditional Chinese medicine freckle-removing facial film, with Radix Angelicae Sinensis, Flos Chrysanthemi, the Radix Angelicae Dahuricae, the Pseudobulbus Bletillae (Rhizoma Bletillae), Rhizoma Typhonii, Radix Ampelopsis, Flos Caryophylli, Semen phaseoli radiati, Lithargyrum, Borneolum Syntheticum, Sal, propolis, Radix Arnebiae (Radix Lithospermi), Radix Rubiae, Cortex Magnoliae Officinalis, Flos Carthami, Lignum Sappan, Radix Paeoniae Rubra, Caulis Akebiae, Retinervus Luffae Fructus, Herba Menthae, Borneolum Syntheticum for active fraction preparation.Disclosed in these two documents, formula all have employed leaded medical material Lithargyrum, and we have also found that in pharmacological evaluation the compositions prepared according to formula disclosed in these two documents is all show plumbous absorption and accumulation in growing animal experiment really, and according to cosmetics health specification 2007 editions, in cosmetics, lead tolerance is the highest is limited to 40mg/kg.As leaded in fruit cosmetic prescription, too high lead tolerance can affect its examination & approval, sell and apply, even and leaded medicine external, also the problem of chronic lead poisoning can be produced when life-time service, as whitening class Chinese medicine cosmetic, can long-term safety use be its research and development in will faced by matter of utmost importance.
Summary of the invention:
For solving the problem, the invention provides a kind of Chinese medicine external compositions, being made up of with the pharmaceutic adjuvant being applicable to external Chinese medicine and Chinese medicine extract, it is characterized in that the formula of described Chinese medicine and Chinese medicine extract contains following composition with crude drug gauge:
Radix Ginseng 15-40 part, Ganoderma 15-40 part, Flos Rosae Rugosae 15-40 part, Herba Spirodelae 15-40 part, Fructus Mume 5-20 part, Fructus Gleditsiae Abnormalis 15-40 part, Faeces Passeris 15-40 part (feces for ploceidae animal Passeris montani saturati (Passer montanus saturatus Stejneger)), Pseudobulbus Bletillae (Rhizoma Bletillae) 15-40 part, Radix Angelicae Dahuricae 15-40 part, Rhizoma Typhonii 15-40 part, Radix Ampelopsis 5-20 part, Flos Carthami (Carthamus tinctorius L. Flos Carthami) 15-40 part, Borneolum Syntheticum 5-20 part, Lithargyrum 5-20 part.(wherein " part " refers to parts by weight)
Described formula is preferably Radix Ginseng 20-30 part with crude drug gauge, Ganoderma 20-30 part, Flos Rosae Rugosae 20-30 part, Herba Spirodelae 20-30 part, Fructus Mume 7-15 part, Fructus Gleditsiae Abnormalis 20-30 part, Faeces Passeris 20-30 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 20-30 part, Radix Angelicae Dahuricae 20-30 part, Rhizoma Typhonii 20-30 part, Radix Ampelopsis 7-15 part, Flos Carthami 20-30 part, Borneolum Syntheticum 7-15 part, Lithargyrum 5-15 part.
Described formula is preferably Radix Ginseng 25 parts with crude drug gauge, Ganoderma 25 parts, Flos Rosae Rugosae 25 parts, 25 parts, Herba Spirodelae, Fructus Mume 10 parts, Fructus Gleditsiae Abnormalis 25 parts, Faeces Passeris 25 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 25 parts, the Radix Angelicae Dahuricae 25 parts, Rhizoma Typhonii 25 parts, Radix Ampelopsis 10 parts, 25 parts, Flos Carthami, Borneolum Syntheticum 10 parts, Lithargyrum 10 parts.
Described formula also contains Rhizoma Atractylodis Macrocephalae 5-20 part with crude drug gauge.
Described formula also contains Poria 5-20 part with crude drug gauge.
Described formula also contains Bombyx Batryticatus 5-20 part with crude drug gauge.
Described formula also contains 5-20 part of leading a cow in vain with crude drug gauge.
Described topical composition, is characterized in that in the formula of described Chinese medicine and Chinese medicine extract: 1) Lithargyrum is ground into fine powder; 2) Borneolum Syntheticum is ground into fine powder or with dissolve with ethanol; 3) preparation of other medical materials is become extract.By step 1), 2), 3) after the mixing of the product that obtains, be prepared into described topical composition with pharmaceutic adjuvant.
Described extract is preferably water or ethanol extraction.
Described formula is with crude drug gauge also containing Margarita 5-20 part, and described Margarita is ground into fine powder and mixes with other Chinese medicines and Chinese medicine extract.
In described formula, Fructus Gleditsiae Abnormalis can replace with equivalent Fructus Gleditsia.
Described topical composition preparation becomes ointment, ointment, gel, liniment, facial film and lotion (lotion).
Described topical composition, its lead tolerance is less than 40mg/kg.
Topical composition provided by the invention, by preferred Chinese medicine core formulation, the effect of whitening is not only enhanced compared with existing Chinese medicine, the effect improving skin quality can also be played, particularly compared with the existing whitening Chinese medicament compositions containing Lithargyrum, significantly can reduce the Transdermal absorption amount of the leaded Chinese medicines such as Lithargyrum, play determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, lower the effect of leaded medical material side effect.And test discovery through us, on core formulation basis, increase the medical material being applicable to external whitening that other are different again, all do not affect the effect of core formulation, and after core formulation deducts some taste medical materials, while whitening, anti-aging effects decline to some extent, the more important thing is that plumbous Transdermal absorption amount significantly increases, illustrate that core formulation is except producing whitening and improving except the effect of skin quality, the more important thing is and can suppress the leaded side effects of pharmaceutical drugs such as Lithargyrum, thus the life-time service safety of provided topical composition is provided while realizing whitening effect.
Detailed description of the invention:
The preparation technology of Chinese medicine and Chinese medicine extract:
The topical composition that the embodiment of the present invention is supplied to, by the formula of Chinese medicine and Chinese medicine extract: 1) Lithargyrum is ground into fine powder; 2) by Borneolum Syntheticum dissolve with ethanol; 3) preparation of other medical materials is become extract (except the Margarita powder of embodiment 10); By step 1), 2), 3) obtain Chinese medicine and Chinese medicine extract, 4 after the mixing of the product that obtains) Chinese medicine and Chinese medicine extract are prepared topical composition as active component and pharmaceutic adjuvant.Wherein step 3) is preferably prepared becomes water extract, and extraction process is as follows:
Add deionized water by after pulverizing medicinal materials according to weight ratio 8-10, being heated to boil keeps 25-30min, filters, filtrate reduced in volume or obtain water extract to dry or lyophilizing.
In embodiment 10, with step 1), 2 after Margarita being ground into powder), 3) in product mix after obtain Chinese medicine and Chinese medicine extract, then Chinese medicine and Chinese medicine extract and pharmaceutic adjuvant are prepared topical composition.
The Lithargyrum adopted in embodiment is industrial lead oxide (PbO, content > 99%)
The formula of Chinese medicine and Chinese medicine extract in table 1 embodiment 1-10
Chinese medicine in embodiment 1-10 and Chinese medicine extract all become preparation according to following topical composition formulated, wherein embodiment 1 is prepared respectively according to different dosage form becomes ointment 1, ointment 1, gel 1, liniment 1, embodiment 2 ~ 10 by that analogy, Chinese medicine and Chinese medicine extraction addition calculate with gained preparation lead tolerance 40mg/kg, all preparations all with the formula of different dosage form and compound method as follows:
Ointment:
Chinese medicine and Chinese medicine extract, tristerin 35g stearic acid 120g liquid Paraffin 60g white vaseline 10g lanoline 50g triethanolamine 4ml ethyl hydroxybenzoate lg distilled water adds to 1000g.
By oil-phase component (i.e. tristerin, stearic acid, liquid Paraffin, vaseline, lanoline)
Be heated to 80 respectively with water-phase component (Chinese medicine and Chinese medicine extract, triethanolamine, ethyl hydroxybenzoate are scattered in distilled water), DEG C the oil phase of melting added in aqueous phase, stir and get final product.
Ointment:
Get Chinese medicine and Chinese medicine extract suitable quantity of water is disperseed, then according to eight parts of vaseline, then both are mixed, obtain 1000g emulsifiable paste by the proportional arrangement ointment base of a liquid paraffin, a lanoline.
Gel:
Acritamer 940 2g ethanol 10g glycerol 50g polyoxyethylene sorbitan monoleate 2g
Ethyl hydroxybenzoate 1g sodium hydroxide 4g distilled water adds to 1000g
Carbomer is mixed with polyoxyethylene sorbitan monoleate and 300ml distilled water, sodium hydroxide adds liquid after being dissolved in 100ml water and stirs evenly, again ethyl hydroxybenzoate and adding gradually after being dissolved in ethanol is stirred evenly, Chinese medicine and Chinese medicine extract soluble in water after add gradually and stir evenly, the water supplying surplus stirs evenly and obtains gel.
Liniment:
Polyvinyl alcohol 12440.0g, ethanol 100ml, distilled water 400ml, Chinese medicine and Chinese medicine extract, with 75% ethanol dispersion, get after polyvinyl alcohol 124 adds water and make fully to expand, heating for dissolving in water-bath, adds with the Chinese medicine of ethanol dispersion and Chinese medicine extract to 1000g.
Unleaded example 1 ~ 10, compared with the embodiment of jack per line, difference is not add Lithargyrum, and other recipe optimization are just the same.
Comparative example 1.3 ~ 1.5, respectively based on the formula of embodiment 3 ~ 5, deducts the Radix Ginseng in formula separately.
Comparative example 2.3 ~ 2.5, respectively based on the formula of embodiment 3 ~ 5, deducts the Ganoderma in formula separately.
Comparative example 3.3 ~ 3.5, respectively based on the formula of embodiment 3 ~ 5, deducts the Fructus Gleditsiae Abnormalis in formula separately.
Comparative example 4.3 ~ 4.5, respectively based on the formula of embodiment 3 ~ 5, deducts the Herba Spirodelae in formula separately.
Comparative example 5.3 ~ 5.5, respectively based on the formula of embodiment 3 ~ 5, deducts the Flos Carthami in formula separately.
The In-vitro Inhibitory Effect of Pharmacological Examples 1 tyrosinase activity and cytotoxicity contrast experiment
According to list of references 1 " several whitening active material is to the In-vitro Inhibitory Effect of tyrosinase activity and cytotoxicity " (Zhang Chunxiang etc., Chinese biochemical drug magazine, the 26th volume the 2nd phase in 2005; The Chinese medicine that method 72-75) obtains embodiment, unleaded example and comparative example and Chinese medicine extract carry out pharmacology contrast experiment.
Adopt and comparatively close B-16 cell on human body melanocyte physiology and medicine direct effect.
Experiment material:
Tryrosinase, levodopa (L-DOPA); Pancreatin; RPMI culture fluid; Lactic acid dehydrogenase (LDH) test kit,
Tumor cell vaccine (B-16 cell), BBHF-16CO
2incubator, 94 well culture plates, DG5031 enzyme-linked immunosorbent assay instrument
Cell culture processes
Select the same generation cell of exponential phase, use 0.25% trypsinization, centrifugal, abandon supernatant, precipitation adds RPMI1640 culture fluid, and piping and druming makes it to become single cell suspension, and adjustment cell number is 4*10
4individual/mL, the 96 every holes of orifice plate add cell suspension 100 μ L, then supplement culture fluid 100 μ L, after bed board 24h, abandon supernatant, add the RPMI1640 culture fluid 200 μ L containing variable concentrations Chinese medicine and Chinese medicine extract, 37, DEG C 5%CO
2cultivate under saturated moist condition, each concentration establishes 6 multiple holes, and control wells adds the RPMI1640 culture fluid of not dosing, cultivates 3d.Medicinal liquid is changed once after 1.5d.
The mensuration of intracellular tyrosine enzymatic activity, the mensuration of the level of LDH in cell conditioned medium liquid, all measures according to method disclosed in list of references 1.
Dosage is amounted to into crude drug amount (with medical material weighing scales all in formula) and is calculated.Crude drug total amounts 325 parts as all in embodiment in table 11, then the aforementioned RPMI1640 culture fluid concentration containing Chinese medicine and Chinese medicine extract added is equivalent to 3.25mg crude drug/mL, in embodiment 2, all crude drug total amounts are 365 parts, then the aforementioned RPMI1640 culture fluid concentration containing Chinese medicine and Chinese medicine extract added is equivalent to 3.65mg crude drug/mL, by that analogy, as having Lithargyrum or Margarita in formula, then make suspension by adding according to formula proportion after being ground into fine powder when preparing RPMI1640 culture fluid (hereinafter referred to as culture fluid) containing Chinese medicine and Chinese medicine extract, in culture fluid, Lithargyrum's micropowder is added in the ratio of 200 μ g/mL for embodiment 1, in culture fluid, Margarita powder is added in the ratio of 200 μ g/mL.The particle size range of Lithargyrum's micropowder and Margarita powder is 1-3 μm.
Inhibitory activity against tyrosinase (meansigma methods) and LDH concentration (meansigma methods) experimental result see the following form 2
Control wells LDH mean concentration is 243.5U/L
LDH is the important indicator of reflection cell membrane integrity.As described in list of references 1, by detecting the level of LDH in cell conditioned medium liquid, the cytotoxicity of detection of drugs compositions can be carried out.Can be found out by above-mentioned two kinds of tests, use the embodiment of the present invention 1 ~ 10 the experimental group of Chinese medicine and Chinese medicine composition is provided, its LDH level raises few, to tyrosinase activity, there is higher suppression ratio, and do not add the unleaded example 1 ~ 10 of Lithargyrum, to the significant decline that the suppression ratio of tyrosinase activity occurs.What the leaded medicines such as Lithargyrum were described adds the suppression ratio and then enhancing whitening effect that really can improve tyrosinase activity.But also shown by the experiment of comparative example 1.3 ~ 1.5 to comparative example 5.3 ~ 5.5, after being deleted core formulation, significantly improving has appearred in LDH concentration, the suppression ratio of tyrosinase activity also declines to some extent simultaneously, illustrate that core formulation is necessary for technique effect of the present invention, the cytotoxicity that all can increase prescription is deleted to its any medical material simply, and reduces its whitening effect.
Pharmacological Examples 2 heavy metal accumulation experiment
Laboratory animal: SD rat, SFP level, half and half, body weight 140-160g, often organize 10.
Experimental technique: adopt the topical composition that each embodiment 3 ~ 8 and comparative example 1.3 ~ 1.5 to comparative example 5.3 ~ 5.5 provide, unification is prepared into liniment, first 24 hours of experimental administration, by first for rat back spinal column both sides cropping again with 8% sodium sulfide depilation, depilation area is 5*5cm
2, every day is administered twice, and each administration 1g also keeps 6h, and guarantees that animal skin stands intact, and successive administration 30 days, sets up blank group simultaneously, gives liniment substrate.Grouping and administration see the following form
After drug withdrawal, fasting 12h, can't help water, gets a burst arteriovenous sacrificed by exsanguination on an empty stomach next day.Get liver, after nephridial tissue weighs, detect lead tolerance, experimental result as following table (
xn=10, ng/g):
Heavy metal accumulation experiment shows, adopt the experimental group of embodiment 3-8, the lead tolerance of hepatic and renal tissue is significantly lower than the experimental group (P < 0.05) adopting comparative example, explanation, when adopting core formulation, can significantly to suppress in medicine leaded accumulation in hepatic and renal tissue, when significantly improving has appearred in lead content in hepatic and renal tissue after being deleted core formulation, illustrate that core formulation is necessary for technique effect of the present invention, all can increase plumbous accumulation to deleting of its any medical material simply, affect the safety of its life-time service.
Claims (8)
1. a Chinese medicine external compositions, is made up of with the pharmaceutic adjuvant being applicable to external Chinese medicine and Chinese medicine extract, it is characterized in that formula is preferably Radix Ginseng 20-30 part with crude drug gauge, Ganoderma 20-30 part, Flos Rosae Rugosae 20-30 part, Herba Spirodelae 20-30 part, Fructus Mume 7-15 part, Fructus Gleditsiae Abnormalis 20-30 part, Faeces Passeris 20-30 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 20-30 part, Radix Angelicae Dahuricae 20-30 part, Rhizoma Typhonii 20-30 part, Radix Ampelopsis 7-15 part, Flos Carthami 20-30 part, Borneolum Syntheticum 7-15 part, Lithargyrum 5-15 part.
2. topical composition as claimed in claim 1, is characterized in that described formula counts Radix Ginseng 25 parts with crude drug consumption, Ganoderma 25 parts, Flos Rosae Rugosae 25 parts, 25 parts, Herba Spirodelae, Fructus Mume 10 parts, Fructus Gleditsiae Abnormalis 25 parts, Faeces Passeris 25 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 25 parts, the Radix Angelicae Dahuricae 25 parts, Rhizoma Typhonii 25 parts, Radix Ampelopsis 10 parts, 25 parts, Flos Carthami, Borneolum Syntheticum 10 parts, Lithargyrum 10 parts.
3. topical composition as claimed in claim 1 or 2, is characterized in that described formula with crude drug gauge also containing Rhizoma Atractylodis Macrocephalae 5-20 part.
4. topical composition as claimed in claim 1 or 2, is characterized in that described formula with crude drug gauge also containing Poria 5-20 part.
5. topical composition as claimed in claim 1 or 2, is characterized in that described formula with crude drug gauge also containing Bombyx Batryticatus 5-20 part.
6. topical composition as claimed in claim 1 or 2, is characterized in that described formula with crude drug gauge also containing 5-20 part of leading a cow in vain.
7. topical composition as claimed in claim 1 or 2, is characterized in that described formula with crude drug gauge also containing Margarita 5-20 part.
8. topical composition as claimed in claim 1 or 2, is characterized in that its lead tolerance is less than 40mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310556120.5A CN103550522B (en) | 2013-11-11 | 2013-11-11 | A kind of Chinese medicine composition with whitening effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310556120.5A CN103550522B (en) | 2013-11-11 | 2013-11-11 | A kind of Chinese medicine composition with whitening effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103550522A CN103550522A (en) | 2014-02-05 |
| CN103550522B true CN103550522B (en) | 2015-11-04 |
Family
ID=50004994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310556120.5A Expired - Fee Related CN103550522B (en) | 2013-11-11 | 2013-11-11 | A kind of Chinese medicine composition with whitening effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550522B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214974A (en) * | 2016-08-29 | 2016-12-14 | 李烨 | A kind of Chinese medicine composition pressing down scar and whitening |
| CN108485849A (en) * | 2018-03-30 | 2018-09-04 | 重庆正刚中医骨科医院有限公司 | Secret plant medicated soap |
| CN110833187A (en) * | 2019-08-23 | 2020-02-25 | 杭州三式化妆品有限公司 | Enzyme stock solution and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500472A (en) * | 2002-11-15 | 2004-06-02 | 赵建军 | Beauty liquid |
| CN101219096A (en) * | 2007-01-08 | 2008-07-16 | 胡馨元 | Pharmaceutical composition for removing speckle, production method and using method thereof |
| CN101978943A (en) * | 2010-10-28 | 2011-02-23 | 李桂宾 | Medicinal skin whitening cream and preparation method thereof |
-
2013
- 2013-11-11 CN CN201310556120.5A patent/CN103550522B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500472A (en) * | 2002-11-15 | 2004-06-02 | 赵建军 | Beauty liquid |
| CN101219096A (en) * | 2007-01-08 | 2008-07-16 | 胡馨元 | Pharmaceutical composition for removing speckle, production method and using method thereof |
| CN101978943A (en) * | 2010-10-28 | 2011-02-23 | 李桂宾 | Medicinal skin whitening cream and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103550522A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102018937B (en) | Medicament for treating acne and preparation method thereof | |
| CN102440928B (en) | Traditional Chinese medicine composition and preparation with skin microcirculation promotion function and preparation method thereof | |
| CN102038897A (en) | Quality control method of traditional Chinese medical preparation | |
| CN103550522B (en) | A kind of Chinese medicine composition with whitening effect | |
| CN102389515A (en) | External traditional Chinese medicine liniment for treating acne dermatosis and preparation method thereof | |
| CN102283895A (en) | Preparation technology and production method of integrated novel Lingguizhugan decoction dosage form | |
| CN104306447B (en) | A kind of pair of rattan micro emulsion gels and preparation method thereof | |
| CN101590212A (en) | Treatment mental sickness Chinese medicine composition and preparation method thereof, purposes and quality control | |
| CN1994353A (en) | A superfine powdered Chinese medicinal composition and preparation method thereof | |
| CN103349737B (en) | Traditional Chinese medicine composite for treating headache and preparation method of traditional Chinese medicine composite | |
| CN102706978A (en) | Wild chrysanthemum flower extractive and fingerprint spectrum detection method thereof | |
| CN100502867C (en) | Preparation of sinomenine as antineoplastic medicament | |
| CN101664452B (en) | Drug combination containing musk | |
| CN102727793A (en) | Yikunning pharmaceutical composition solid lipid nanosphere preparation | |
| CN102100892A (en) | Preparation technology and production method of integrated Xiaojianzhong decoction novel dosage form | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN111297971B (en) | Composition for treating breast cancer and preparation method and application thereof | |
| CN101766699A (en) | Medicinal combination containing musk | |
| CN1651018B (en) | Preparation method of medicinal composition for treating upper respiration duct infection | |
| CN103239528A (en) | Traditional chinese medicine composition | |
| CN108126154A (en) | A kind of preparation method and application for the nano dispersion fluid for treating obstruction of collaterals by blood stasis arthralgia-syndrome pain | |
| CN102430029B (en) | A kind of nano microcapsule for six ingredients with rehmannia and preparation technology thereof | |
| CN107519438A (en) | Treat composition of pruitus and preparation method and application | |
| CN102100769A (en) | Preparation technique for ephedra and bighead atractylodes rhizome decoction in novel formed formulation and production method thereof | |
| CN103656433A (en) | Natural pharmaceutical composition as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190926 Address after: 300350 102-02, floor 5, building 18, jinhaoyuan, xianshuigu Town, Jinnan District, Tianjin Patentee after: Tianjin Qianlang Biotechnology Co., Ltd. Address before: 300074, A, building 1, Zhongtian building, No. 1301, rehabilitation Road, Tianjin, Nankai District Patentee before: TIANJIN YIYANTANG BIOTECHNOLOGY CO., LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151104 Termination date: 20191111 |